Prospective randomized clinical studies involving reirradiationNieder, C., Langendijk, J. A., Guckenberger, M. & Grosu, A. L., Oct-2016, In : Strahlentherapie und onkologie. 192, 10, p. 679-686 8 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Background Reirradiation is a potentially useful option for many patients with recurrent cancer. The purpose of this study was to review all recently published randomized trials in order to identify methodological strengths and weaknesses, comment on the results, clinical implications and open questions, and give advice for the planning of future trials.
Materials and methods Systematic review of trials published between 2000 and 2015 (databases searched were PubMed, Scopus and Web of Science).
Results We reviewed 9 trials, most of which addressed reirradiation of head and neck tumours. The median number of patients was 69. Trial design, primary endpoint and statistical hypotheses varied widely. The results contribute mainly to decision making for reirradiation of nasopharynx cancer and bone metastases. The trials with relatively long median follow-up confirm that serious toxicity remains a concern after high cumulative total doses.
Conclusion Multi-institutional collaboration is encouraged to complete sufficiently large trials. Despite a paucity of large randomized studies, reirradiation has been adopted in different clinical scenarios by many institutions. Typically, the patients have been assessed by multidisciplinary tumour boards and advanced technologies are used to create highly conformal dose distributions.
|Number of pages||8|
|Journal||Strahlentherapie und onkologie|
|Early online date||17-Aug-2016|
|Publication status||Published - Oct-2016|
- Radiotherapy, Radiation oncology, Radiation retreatment, Research design, Randomized controlled trial, SQUAMOUS-CELL CARCINOMA, RECURRENT NASOPHARYNGEAL CARCINOMA, INTENSITY-MODULATED RADIOTHERAPY, THERAPY ONCOLOGY GROUP, PHASE-II, RADIATION-THERAPY, NECK-CANCER, PROGRESSIVE GLIOBLASTOMA, MALIGNANT GLIOMA, CONTROLLED-TRIAL